KR101997206B1 - 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법 - Google Patents

리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법 Download PDF

Info

Publication number
KR101997206B1
KR101997206B1 KR1020177024678A KR20177024678A KR101997206B1 KR 101997206 B1 KR101997206 B1 KR 101997206B1 KR 1020177024678 A KR1020177024678 A KR 1020177024678A KR 20177024678 A KR20177024678 A KR 20177024678A KR 101997206 B1 KR101997206 B1 KR 101997206B1
Authority
KR
South Korea
Prior art keywords
irinotecan
administered
formulation
patient
liposomal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177024678A
Other languages
English (en)
Korean (ko)
Other versions
KR20170104638A (ko
Inventor
엘리엘 베이에버
나브리트 딘드사
조나단 바질 핏제랄드
피터 라이빈스
빅터 모요
클레트 니위키자
재연 김
Original Assignee
입센 바이오팜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101997206(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 입센 바이오팜 리미티드 filed Critical 입센 바이오팜 리미티드
Publication of KR20170104638A publication Critical patent/KR20170104638A/ko
Application granted granted Critical
Publication of KR101997206B1 publication Critical patent/KR101997206B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177024678A 2012-06-13 2013-06-12 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법 Active KR101997206B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261659211P 2012-06-13 2012-06-13
US61/659,211 2012-06-13
US201361784382P 2013-03-14 2013-03-14
US61/784,382 2013-03-14
PCT/US2013/045495 WO2013188586A1 (en) 2012-06-13 2013-06-12 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157000450A Division KR101776808B1 (ko) 2012-06-13 2013-06-12 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018996A Division KR20190107010A (ko) 2012-06-13 2013-06-12 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법

Publications (2)

Publication Number Publication Date
KR20170104638A KR20170104638A (ko) 2017-09-15
KR101997206B1 true KR101997206B1 (ko) 2019-07-08

Family

ID=48692681

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157000450A Active KR101776808B1 (ko) 2012-06-13 2013-06-12 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법
KR1020197018996A Withdrawn KR20190107010A (ko) 2012-06-13 2013-06-12 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법
KR1020177024678A Active KR101997206B1 (ko) 2012-06-13 2013-06-12 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020157000450A Active KR101776808B1 (ko) 2012-06-13 2013-06-12 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법
KR1020197018996A Withdrawn KR20190107010A (ko) 2012-06-13 2013-06-12 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법

Country Status (21)

Country Link
US (10) US9452162B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP2861210B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP6310911B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR101776808B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN110051631A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2013202947B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014031088A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2875824C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK3266456T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2632915T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL235937B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN11099A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX376937B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ702469A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL3266456T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2861210T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2663450C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI3266456T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (3) TWI729492B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013188586A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201408804B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147867B2 (en) * 2004-05-03 2012-04-03 Hermes Biosciences, Inc. Liposomes useful for drug delivery
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
KR102501566B1 (ko) * 2014-01-14 2023-02-17 넥타르 테라퓨틱스 병용 기반 치료 방법
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
AU2015360761B2 (en) * 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) * 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
ES2848118T3 (es) 2015-08-20 2021-08-05 Ipsen Biopharm Ltd Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer
BR112018002941B1 (pt) * 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
US10894044B2 (en) 2015-09-16 2021-01-19 Board Of Regents, The University Of Texas System Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
WO2017066726A1 (en) 2015-10-16 2017-04-20 Merrimack Pharmaceuticals, Inc. Stabilizing camptothecin pharmaceutical compositions
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
BR112018072988A2 (pt) * 2016-05-18 2019-04-09 Ipsen Biopharm Ltd. irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula
US11071726B2 (en) * 2016-11-02 2021-07-27 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
EP3866812A1 (en) * 2018-10-17 2021-08-25 BioLineRx Ltd. Treatment of metastatic pancreatic adenocarcinoma
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
EP3911353A1 (en) * 2019-01-17 2021-11-24 BioLineRx Ltd. Specific combination therapy for treatment of pancreatic cancer
BR112022013685A2 (pt) 2020-01-10 2022-09-06 R Pharm Us Operating Llc Composições de ixabepilona
US11286344B2 (en) 2020-01-10 2022-03-29 Tyndall Formulation Services, LLC Polymer excipients for drug delivery applications
EP4087535A1 (en) * 2020-01-10 2022-11-16 Tyndall Formulation Services, LLC Formulations of sn-38 with poly(amino acid) block polymers
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272737A1 (en) 2004-06-03 2005-12-08 Jianping Chen Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor
JP2012503640A (ja) 2008-09-26 2012-02-09 センター リージョナル ド ルッタ コントレ ル キャンサー ダンジェ Ｆｏｌｆｉｒｉ治療における５−フルオロウラシル用量の個別最適化方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2628659A (en) * 1951-01-17 1953-02-17 Charles R Carpenter Convertible furniture article
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
AU4990397A (en) 1996-10-22 1998-05-15 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
WO2000023052A1 (en) 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7025988B2 (en) 2000-02-04 2006-04-11 Lipoxen Technologies Limited Liposomes
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
ATE322265T1 (de) 2000-05-15 2006-04-15 Celgene Corp Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
IL153676A0 (en) 2000-06-30 2003-07-06 Inex Pharmaceuticals Corp Liposomal pharmaceutical compositions
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
JP2004525138A (ja) 2001-03-26 2004-08-19 アルザ・コーポレーシヨン 治療剤の改良された細胞内送達のためのリポソーム組成物
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
EP1408974A2 (en) 2001-07-23 2004-04-21 Epidauros Biotechnologie AG Methods for treatment of cancer using irinotecan based on ugt1a1
US20030077833A1 (en) * 2001-09-07 2003-04-24 Queen's University At Kingston Diagnositc methods for determining susceptibility to convulsive conditions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ITBO20010610A1 (it) 2001-10-05 2003-04-05 Haworth S P A Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo
AU2003237864B2 (en) 2002-05-15 2008-12-18 California Pacific Medical Center Delivery of nucleic acid-like compounds
CA2494451A1 (en) 2002-05-31 2003-12-11 Transmolecular, Inc. Treatment of cell proliferative disorders with chlorotoxin
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
RS20150135A1 (en) 2003-05-30 2015-08-31 Genentech Inc. TREATMENT WITH ANTI-VEGF ANTIBODIES
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US8147867B2 (en) 2004-05-03 2012-04-03 Hermes Biosciences, Inc. Liposomes useful for drug delivery
KR100889139B1 (ko) 2004-06-01 2009-03-17 테루모 가부시키가이샤 이리노테칸 제제
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7842676B2 (en) 2005-10-25 2010-11-30 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20080269131A1 (en) * 2005-11-10 2008-10-30 Smithkline Beecham Corporation Inhibitors of Akt Activity
US20090148506A1 (en) * 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
DK2338487T3 (da) 2006-01-17 2013-12-09 Abbvie Bahamas Ltd Kombinationsterapi med PARP-inhibitorer
CA2647297A1 (en) 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
KR101153058B1 (ko) * 2006-11-30 2012-06-04 아크레이 가부시키가이샤 Ｕｇｔ1ａ1 유전자 증폭용 프라이머 셋트, 그것을 포함하는 ｕｇｔ1ａ1 유전자 증폭용 시약 및 그 용도
HRP20131113T1 (hr) 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
EP2187869B1 (en) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
EP2197917A1 (en) * 2007-09-28 2010-06-23 Universitätsspital Basel Immunoliposomes for treatment of cancer
KR20100102607A (ko) 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
CN101888777A (zh) 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US20110104256A1 (en) 2008-03-25 2011-05-05 Yaolin Wang Methods for treating or preventing colorectal cancer
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
NZ589086A (en) 2008-04-11 2012-09-28 Merrimack Pharmaceuticals Inc Human serum albumin (HSA) linkers and conjugates thereof
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN102573826A (zh) 2009-05-01 2012-07-11 奥克兹美制药公司 用于治疗癌症的喷他脒组合
MX2012005775A (es) 2009-12-03 2012-06-13 Shanghai Hengrui Pharm Co Ltd Liposoma de irinotecano o su clorhidrato y metodo para la preparacion de los mismos.
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
AU2011282223A1 (en) 2010-07-19 2013-03-07 Bipar Sciences, Inc. Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
CN106432495A (zh) 2010-07-22 2017-02-22 加利福尼亚大学董事会 抗肿瘤抗原抗体及其使用方法
RU2541100C2 (ru) 2010-09-03 2015-02-10 Боард Оф Регентс Оф Зе Юниверсити Оф Небраска Способ и композиция для лечения рака
CN107252417A (zh) 2010-12-06 2017-10-17 梅里麦克制药股份有限公司 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药
AU2011344865B2 (en) 2010-12-14 2017-03-09 Rigshospitalet Entrapment of radionuclides in nanoparticle compositions
EP2675918B1 (en) 2011-02-15 2017-11-08 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
EP2699602B1 (en) 2011-04-19 2017-03-01 Merrimack Pharmaceuticals, Inc. Bispecific anti-igf-1r and anti-erbb3 antibodies
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013201584A1 (en) * 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
CA2881928A1 (en) 2012-04-17 2013-10-24 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2014113167A1 (en) 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
PL2979700T3 (pl) 2013-03-27 2019-03-29 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy zawierający małą dawkę hydratu chlorowodorku irynotekanu
JP2016529284A (ja) 2013-08-27 2016-09-23 ノースイースタン ユニバーシティ ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法
WO2015061592A1 (en) 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
AU2015360761B2 (en) 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
ES2848118T3 (es) 2015-08-20 2021-08-05 Ipsen Biopharm Ltd Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer
BR112018002941B1 (pt) 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
WO2017066726A1 (en) 2015-10-16 2017-04-20 Merrimack Pharmaceuticals, Inc. Stabilizing camptothecin pharmaceutical compositions
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
BR112018072988A2 (pt) 2016-05-18 2019-04-09 Ipsen Biopharm Ltd. irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula
US11071726B2 (en) 2016-11-02 2021-07-27 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272737A1 (en) 2004-06-03 2005-12-08 Jianping Chen Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor
JP2012503640A (ja) 2008-09-26 2012-02-09 センター リージョナル ド ルッタ コントレ ル キャンサー ダンジェ Ｆｏｌｆｉｒｉ治療における５−フルオロウラシル用量の個別最適化方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Digestive and Liver Disease, Vol. 43, pp 912- 916 (2011년)
Journal of Gastrointestinal Oncology, Vol. 2(3), pp 185~194(2011년)
The Pharmacogenomics Journal, Vol. 2, pp 43-47(2002년)

Also Published As

Publication number Publication date
JP2017149783A (ja) 2017-08-31
PT3266456T (pt) 2021-07-28
EP3919048A1 (en) 2021-12-08
AU2018201942A1 (en) 2018-04-12
EP2861210A1 (en) 2015-04-22
US20150374682A1 (en) 2015-12-31
PL3266456T3 (pl) 2021-11-29
US9364473B2 (en) 2016-06-14
AU2018201942B2 (en) 2019-12-05
SI2861210T1 (sl) 2017-10-30
US20220096458A1 (en) 2022-03-31
US20190117643A1 (en) 2019-04-25
HK1248608A1 (en) 2018-10-19
ES2632915T3 (es) 2017-09-18
BR112014031088A8 (pt) 2021-06-22
IL304631A (en) 2023-09-01
US9492442B2 (en) 2016-11-15
US20150182521A1 (en) 2015-07-02
TW201412345A (zh) 2014-04-01
KR20190107010A (ko) 2019-09-18
TWI729492B (zh) 2021-06-01
MX2014015391A (es) 2015-06-17
AU2013202947A1 (en) 2014-01-16
RU2015100529A (ru) 2016-08-10
TW202027727A (zh) 2020-08-01
IN2014DN11099A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-25
US9452162B2 (en) 2016-09-27
WO2013188586A1 (en) 2013-12-19
KR20170104638A (ko) 2017-09-15
JP6857210B2 (ja) 2021-04-14
KR101776808B1 (ko) 2017-09-11
NZ702469A (en) 2017-08-25
RU2018126616A (ru) 2019-03-12
EP3266456A1 (en) 2018-01-10
TW201831168A (zh) 2018-09-01
PL2861210T3 (pl) 2017-12-29
EP2861210B1 (en) 2017-05-03
ES2880089T3 (es) 2021-11-23
DK3266456T3 (da) 2021-07-05
ZA201408804B (en) 2017-06-28
CN104717961A (zh) 2015-06-17
JP6310911B2 (ja) 2018-04-11
DK2861210T3 (en) 2017-07-24
JP2019116517A (ja) 2019-07-18
TWI630924B (zh) 2018-08-01
US20160074382A1 (en) 2016-03-17
US20170065578A1 (en) 2017-03-09
US10980795B2 (en) 2021-04-20
IL294886A (en) 2022-09-01
CA2875824C (en) 2021-05-18
CA2875824A1 (en) 2013-12-19
HK1209627A1 (en) 2016-04-08
KR20150021565A (ko) 2015-03-02
SI3266456T1 (sl) 2022-03-31
IL235937B (en) 2022-08-01
US20160228428A1 (en) 2016-08-11
BR112014031088A2 (pt) 2017-06-27
AU2013274287A1 (en) 2015-01-29
AU2013202947B2 (en) 2016-06-02
IL235937A0 (en) 2015-01-29
PT2861210T (pt) 2017-07-26
EP3266456B1 (en) 2021-05-05
CN110051631A (zh) 2019-07-26
JP2015523355A (ja) 2015-08-13
US20150328156A1 (en) 2015-11-19
RU2663450C2 (ru) 2018-08-06
MX376937B (es) 2025-03-07
US9339497B2 (en) 2016-05-17
AU2013274287B2 (en) 2017-12-21
US20170368056A1 (en) 2017-12-28
US20240226090A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
KR101997206B1 (ko) 리포좀성 이리노테칸을 포함하는 병용 치료요법을 사용하여 췌장암을 치료하기 위한 방법
RU2808427C2 (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан
HK40064914A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
HK40010824A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
HK1248608B (en) Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer
HK1209627B (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170901

Application number text: 1020157000450

Filing date: 20150108

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180611

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180702

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190401

GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190701

Application number text: 1020157000450

Filing date: 20150108

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190701

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190702

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220615

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240617

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20250616

Start annual number: 7

End annual number: 7